Latest Breaking News On - Sio gene - Page 6 : comparemela.com

How Covid-19 is changing rare diseases research

(SIOX) - Sio Gene Therapies Gains After Receiving $11.6M From Arvelle Therapeutics Deal Close

Glioblastoma Multiforme (GBM) Treatments Advancing as FDA Steps Up Measures Due to Rising Incidences

Glioblastoma Multiforme (GBM) Treatments Advancing as FDA Steps Up Measures Due to Rising Incidences PALM BEACH, Fla., Dec. 17, 2020 /PRNewswire/ Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans that involves glial cells. GBM is present in two variants namely, giant cell glioblastoma and gliosarcoma. Gliomas are tumors arising from glial cells and may occur in the spinal cord or the brain, the latter being more common. Gliomas are the most common type of brain tumor and can be either supratentorial or infratentorial. Seizure, nausea, headache, hemiparesis and memory loss are some of the common symptoms observed in the patients suffering from GBM. GBM is most commonly found in male with the age of 65 years and above. Increasing habits of alcohol consumption, changing lifestyle and increasing incidence of seizure are some of the drivers for the growth of GBM market. GBM is generally treated by first surgically removing the tumor then t

Sio Gene Therapies Announces Positive Six-Month Follow-Up Data from Low-Dose Cohort of Phase ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Sio Gene Therapies Announces Positive Six-Month Follow-Up Data from Low-Dose Cohort of Phase . Sio Gene TherapiesDecember 15, 2020 GMT -  Generally well-tolerated with a favorable safety profile in five patients -  Serum beta-galactosidase enzyme activity increased in all patients at all timepoints between Day 7 and Month 6, representing an approximate doubling in enzyme activity after gene transfer -  At Month 6, enzyme activity restored to 23-57% (mean: 38%) of normal reference levels -  All five children demonstrated signs of clinical disease stability as assessed by Vineland-3 Growth Scale Value, Upright and Floor Mobility, and Clinical Global Impression (CGI) scales